|
|
Vaccine Detail
|
HLA-A2-Binding TYR/MART-1/gp100 Multipeptide-Pulsed Autologous Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: HLA-A2-Binding TYR/MART-1/gp100 Multipeptide-Pulsed Autologous Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007496
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: gp100, MLANA, Tyrosinase
- gp100 (PMEL)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- MLANA
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Tyrosinase
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted melanoma-associated antigen peptides tyrosinase (TYR), MART-1(melanoma antigen recognized by T-cells) and melanoma antigen glycoprotein 100 (gp100), with potential immunomodulating and antineoplastic activity. Upon vaccination, HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount an anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against Tyr-, MART-1 and gp100-expressing cancer cells, resulting in tumor cell lysis. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity. (NCIT_C90569).
|
| Host Response |
|
|
| References |
NCIT_C90569: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90569]
|
|
